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INTRODUCTION
Randomized controlled trials among patients with schi-
zophrenia have shown that ,20% improvement in the first
two weeks of treatment predicts nonresponse after 12
weeks. The findings have been consistent for patients
treated with both conventional (1) and second-generation
antipsychotic (AP) drugs (2). However, despite the lack of
evidence regarding the length of time that clinicians should
pursue one treatment regimen, most psychiatric textbooks
and practice guidelines suggest that patients should be
treated for at least four to six weeks with one AP (3-5) before
switching to another (6).
Large pragmatic trials with chronic patients, such as the
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) (7), have found no benefit from switching AP
drugs (8,9). No studies have considered less chronic
patients, such as patients with recent-onset schizophrenia
(i.e., less than five years of illness duration).
We investigated responses to APs and switching strate-
gies in patients with recent-onset schizophrenia. We used
the IPAP algorithm, which is a well-defined algorithm for
treating schizophrenia (4,10).
METHODS
Study Design
The present study was a pilot, single-center, open,
randomized trial. The trial was conducted in an outpatient
setting at the Institute of Psychiatry (IPq) at the Hospital das
Clı´nicas at the University of Sa˜o Paulo Medical School, Sa˜o
Paulo/SP, Brazil. All of the subjects signed informed
consent forms. The study was approved by the local ethics
committee (protocol 0802/08) and was registered at
Clinicaltrials.gov: NCT01016145. The study was conducted
in accordance with the Declaration of Helsinki (1975,
revised in 1989). The subjects were randomized to receive
either first-generation antipsychotics (FGAs) or second-
generation antipsychotics (SGAs). Once assigned to the
FGA or SGA groups, the choice of drug within the class was
left to the discretion of each treating psychiatrist. None of
the included patients were regularly taking AP drugs upon
entering the study.
The treatment followed the IPAP algorithm, which states
that patients should be treated in monotherapy with either a
first-generation (FGA) or second-generation antipsychotic
(SGA) for at least two 4- to 6-week trials. The patients who
failed to respond to these two trials were considered to be
resistant to treatment and were eligible for clozapine.
The subjects were assessed with the Positive and Negative
Syndrome Scale (PANSS) (11) at baseline and at weeks 2, 4,
6, 8, and 12.
The PANSS ratings were performed by three blinded and
independent psychiatrists. The scale showed high reliability
(intraclass correlation coefficient = 0.865).
Subjects
Patients between ages 18 and 45 years who met the DSM-
IV TR criteria (12) for schizophrenia or schizoaffective
disorders were included in the study. The patients had #5
years of illness and an exacerbation of symptoms with a
minimum PANSS total score of 60 and a minimum Clinical
Global Impression-Severity (CGI-S) score of 4.
The exclusion criteria were the presence of cognitive
disorders of neurological etiology, a history of refractoriness
to AP (i.e., previous or active use of clozapine), and active
substance abuse.
Pharmacotherapy
The following APs were allowed in the study:
FGAs
N haloperidol, 5-10 mg/day.
N chlorpromazine, 25-800 mg/day
N trifluoperazine, 5-10 mg/day
SGAs
N olanzapine, 5-20 mg/day.
N risperidone, 1-6 mg/day
N quetiapine, 25 a 800 mg/day
N ziprasidone, 80-160 mg/day
N aripiprazole, 15-30 mg/day
Objectives
The primary aim of the study was to assess treatment
resistance among patients with recent-onset schizophrenia
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(12):1479-1482 DOI:10.6061/clinics/2012(12)20
1479
or schizoaffective disorder. The study tested the hypothesis
that no improvement in the PANSS score after two weeks of
treatment was associated with nonresponse at 12 weeks. The
secondary objectives were to evaluate the effectiveness of
switching antipsychotic drugs after four weeks of treatment
and to compare the response rate between the FGAs and
SGAs.
Response definition
Response was defined as a $30% decrease in the PANSS
score at any time in the study.
Improvement (in the first two weeks) was defined as a
$20% decrease in the PANSS score.
Statistical analyses
The demographic and outcome variables (response/
nonresponse) were compared between the groups using t-
tests, Chi-squared test, and Fischer’s exact tests. To compare
the overall treatment effect over time, a repeated measures
analysis of variance (ANOVA) was used; treatment was the
between-group factor, and time was the within-subject
factor. An analysis of covariance was performed to evaluate
the treatment response at two weeks, and baseline PANSS
was used as a covariate. The significance level was set at
0.05.
RESULTS
Forty-nine subjects were screened for study eligibility,
and 22 were included and randomized.
All of the patients had recent-onset schizophrenia or
schizoaffective disorder and were not taking APs when they
were included in the study. The baseline characteristics of
all the participants are described in Table 1.
Twelve patients were randomized to receive SGAs, and
10 were randomized to receive FGAs (Figure 1). One patient
withdrew consent after being randomized but before
receiving treatment, and another patient could not be
assessed because of catatonic mutism; therefore, we
analyzed the baseline data from 20 patients (Table 1). Two
patients withdrew from the study because they did not have
a caregiver to transport them to the visits (n = 2), and one
patient was excluded because of gastric cancer. All of the
Table 1 - Patient baseline characteristics (n = 20).
Characteristic
Male/Female (n) 10/10
Paranoid schizophrenia (n) 17
Catatonic schizophrenia (n) 1
Schizoaffective disorder (n) 2
Age at screening (years, mean¡SD) 30.05¡8.06
Duration of untreated psychosis (years, mean¡SD) 1.65¡2.66
Illness duration (years, ¡SD) 3.25¡3.14
Total PANSS score (mean ¡SD) 94.16¡21.99
CGI severity (mean¡SD) 5.35¡0.75
CGI: clinical global impression.
PANSS: positive and negative syndrome scale.
Figure 1 - A patient allocation flow diagram. FGA: First-generation antipsychotic; SGA: second-generation antipsychotic.
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dropouts occurred in the SGA group before they had
received treatment. Ultimately, the data from 17 patients
were analyzed (7 SGA and 10 FGA patients).
After 12 weeks, 13 patients responded to treatment and 4
did not. The number of responders was similar in each
group (FGA=7, SGA=6, p= 1.0). The mean PANSS reduc-
tion from baseline was also similar between the groups.
Independent sample t-tests demonstrated that the FGA
and SGA groups were comparable in the patient demo-
graphic characteristics and treatment responses throughout
the study. Because more than 50% of the patients switched
their APs (7 from FGA and 5 from SGA), and there was no
observable difference between the SGA and FGA groups,
we conducted a pooled analysis of all the patients to assess
the correlation between the 2-week improvements and 12-
week responses.
At 12 weeks, the mean PANSS change was 38.74%. This
improvement corresponded to a mean decrease of 35 points
(Figure 2).
Repeated measures ANOVA showed the significant effect
of time; there was an accumulated response rate over time.
Five of the 13 responders showed no responses until 4
weeks. Pairwise comparisons between the baseline scores
and weeks 2, 4, 6, 8, and 12 showed a significant change in
the mean PANSS scores starting at week 4 (p,0.05).
A Chi-squared test between the lack of improvement at 2
weeks (at least 20% improvement in the PANSS score)
showed no relationship to the 12-week nonresponse
(x2 = 0.60, df = 1, p = 0.57).
The subjects who failed to respond by the end of the study
had lower baseline PANSS scores than the responders (79.25
vs. 91.23, p= 0.02); however, the ANCOVA analysis showed
that a lack of improvement at two weeks failed to predict
treatment nonresponse at 12 weeks (F = 1.907, p= 0.192).
Twelve of the 20 patients switched APs. One patient
switched from an SGA to an FGA after experiencing an
allergic reaction to a single dose of risperidone. The other
AP switches occurred because of a lack of efficacy. In the
patients who switched, 75% responded by the end of the
study, but this rate was not significant when compared to
the patients who did not switch (p = 1.00).
DISCUSSION
We found that lack of improvement in the first two weeks
does not predict nonresponse at 12 weeks. Even the patients
who did not exhibit a minimal PANSS improvement of 20%
at two weeks had responded by 12 weeks. Previous reports
have shown that early nonresponse was predictive of
refractoriness; however, such analyses were based on
patients with chronic and possibly already refractory
schizophrenia (1,2).
As observed in chronic patients (8,9), switching APs was
of little benefit in our study. However, the small sample size
limits the generalizability of our findings.
Physicians tend to switch antipsychotics for different
reasons. Physicians are willing to wait longer for some
drugs than for others because the onset of efficacy is not
exact for all antipsychotics (e.g., risperidone acts faster than
olanzapine) (13).
D2/3 receptors are occupied by the AP in a few hours, but
the clinical response may not occur for weeks (14,15); this
delayed onset of a clinical response can be explained by the
fact that a stable blockade of those receptors may be
necessary before a sustained clinical effect is observed (15).
Because this is a pilot study with a small sample of recent-
onset patients, caution is needed in interpreting the results.
Our study found that lack of improvement in the first two
weeks does not predict treatment resistance in recent-onset
psychosis.
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Figure 2 - PANSS – the mean change from baseline. PANSS: positive and negative syndrome scale, n=17, *p,0.05 vs. baseline, **p,0.01
vs. baseline.
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